PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

PR Newswire

prLean Left

6h ago

Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLCtranslating…

Phase 3 EVOKE-03/KEYNOTE-D46 reports numerically longer progression-free survival and higher response rates, but no statistically significant PFS or OS benefit SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Sacituzumab govitecan (SG) plus pembrolizumab did not…

Factuality

70/100

Political Bias

Lean Left

Ownership

Cision

Country

USA

Region

North America

Language

English

Keywords#Plus Pembrolizumab#Sacituzumab Govitecan#Does Not#Does Not Meet#Endpoints

Read Original ↗

Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC | Pulse Aggregator